7th Jan 2011 07:00
FOR IMMEDIATE RELEASE Verona Pharma plc ("Verona" or the "Company") Company Response to Share Price Movement
7 January 2011- London, UK - The Board of Verona Pharma plc (AIM:VRP.L) notes the rise in the Company's share price. As the Company stated in its Interim Results in September 2010, the Directors are seeking the most compatible and appropriate licensing partner to develop RPL554, its lead programme for diseases of the respiratory tract. The Company is in on-going discussions with a number of potential licensees and these discussions may or may not lead to a deal. The Company will make an official statement to the Market and its shareholders as and when a licence is agreed.
-Ends-
For more information please contact:
Verona Pharma plc Tel: 020 7863 3300 Clive Page, Chairman [email protected] Michael Walker, CEO Evolution Securities Limited Tel: 020 7071 4300
Bobbie Hilliam / Tim Redfern / Esther Lee [email protected]
College Hill Tel: 020 7457 2020
Melanie Toyne Sewell / Nicole Yost / Gemma Howe Mob: 07890 022 814
[email protected] Notes to EditorsAbout Verona Pharma plc
Verona Pharma plc is a life sciences company dedicated to the research, discovery and development of drugs for the treatment of allergic rhinitis (hay fever) and other chronic respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), as well as chronic inflammatory diseases. The Company has three potential drug treatments under development aimed at the respiratory and inflammatory diseases markets, RPL554, Verona's lead product in Phase II, Cough (anti-tussive) and novel anti-inflammatory polysaccharides (NAIPs) for the treatment of a wide range of respiratory and inflammatory diseases.
vendorRelated Shares:
VRP.L